Cart
sales@molnova.com
GSK3β inhibitor II
CAS No. 478482-75-6
GSK3β inhibitor II( —— )
Catalog No. M33773 CAS No. 478482-75-6
GSK3β inhibitor II is a GSK3β inhibitor. GSK3β inhibitor II exhibits the research potential of Alzheimer's disease (AD).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 10MG | 43 | In Stock |
|
| 25MG | 91 | In Stock |
|
| 50MG | 152 | In Stock |
|
| 100MG | 207 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK3β inhibitor II
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK3β inhibitor II is a GSK3β inhibitor. GSK3β inhibitor II exhibits the research potential of Alzheimer's disease (AD).
-
DescriptionGSK3β inhibitor II is an inhibitor ofGSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorGSK-3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number478482-75-6
-
Formula Weight395.22
-
Molecular FormulaC14H10IN3OS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (126.51 mM; Ultrasonic (<60°C)
-
SMILESIc1cccc(CSc2nnc(o2)-c2ccncc2)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Elangovan ND, et al. Screening of potential drug for Alzheimer's disease: a computational study with GSK-3 β inhibition through virtual screening, docking, and molecular dynamics simulation. J Biomol Struct Dyn. 2021 Nov;39(18):7065-7079. ?
molnova catalog
related products
-
CHIR-99021
A potent, specific GSK-3 inhibitor with IC50 of 5 nM and 10 nM for GSK3β and GSK3α, respectively.
-
GS87
GS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells.GS87 potently inhibits growth of AML cells in mice with little effect on normal bone marrow cells. GS87 causes terminal differentiation of AML cells.
-
CP21R7
A high-affinity, selective GSK3β inhibitor that activates canonical Wnt signaling.
